|
|
News Breaks | | | | October 4, 2012 | | 12:37 EDT |  | PPHM | Ayer Capital liquidates 5.38% passive stake in Peregrine
| |
|
News For PPHM From The Last 14 Days Check below for free stories on PPHM the last two weeks. |
|
|
| May 20, 2013 | | 08:50 EDT | | PPHM | Peregrine reaches agreement with FDA on Phase 3 trial design for Bavituximab
Peregrine Pharmaceuticals announced that it has reached agreement with the FDA on a Phase III registration trial design of the company's lead clinical immunotherapeutic candidate bavituximab in second-line non-small cell lung cancer. The trial design was supported by promising data from a Phase IIb trial in patients treated with bavituximab plus docetaxel. The Phase III clinical trial will be a randomized, double-blind, placebo-controlled trial evaluating bavituximab plus docetaxel versus docetaxel alone enrolling approximately 600 patients at sites worldwide. The trial will enroll Stage IIIB/IV non-squamous, NSCLC patients who have progressed after standard front-line treatment. The primary endpoint of the trial will be overall survival. | | | 08:40 EDT | | PPHM | Peregrine trading halted, pending news
 Subscribe for More Information | |
|
|
|
|
|
|
